Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suprachoroidal Triamcinolone for Resistant DME and CRVO
NCT04690608Phase 1Not yet recruiting
- Sponsor
- Tanta University
- Start
- Dec 2024
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of triamcinolone acetonide in diabetic macular edema (DME) and central retinal vein occlusion (CRVO), sponsored by Tanta University. Primary endpoint: Improvement of central macular thickness at 1 month. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
triamcinolone acetonide
03
Conditions
diabetic macular edema (DME)central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on NCT04690608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04690608.